Sarepta Therapeutics Inc

Most Recent

  • uploads///SRPT
    Company & Industry Overviews

    A Look at Sarepta Therapeutics’ Stock Performance

    After its stellar rise from $54.02 on January 8 to a high of $161.51 on September 28, Sarepta stock has seen selling pressure amid the market volatility in October.

    By Kenneth Smith
  • uploads///Exon skipping
    Earnings Report

    BioMarin Has Suffered from Kyndrisa’s Rejection

    The recent fall in BioMarin’s stock price is due to the rejection of its drug Kyndrisa, indicated for Duchenne muscular dystrophy.

    By Jillian Dabney
  • uploads///Graph Part  Oct
    Company & Industry Overviews

    Grifols and Myriad Traded above the 100-Day Moving Averages

    Grifols (GRFS) only fell by 0.34%. It bucked the trend. There were talks that Moody’s upgraded the ratings from “negative” to “stable.”

    By Peter Neil
  • uploads///Graph
    Company & Industry Overviews

    Nektar Therapeutics Sees Setbacks in Plans for Ciproflaxin DPI

    On November 16, 2017, the FDA’s Antimicrobial Drugs Advisory Committee voted down the 14-day regimen and 28-day regimen of Nektar Therapeutics’ ciprofloxacin DPI.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Sarepta or Amarin: Who Is Controlling Expenses Better?

    Amarin is expected to dedicate a much higher percentage of its total sales to SG&A but a lower percentage of its total sales to R&D activities as compared to Sarepta Therapeutics from fiscal 2019 to fiscal 2021.

    By Margaret Patrick
  • uploads///Graph Part  Oct
    Company & Industry Overviews

    Radius Continued to Fall despite Positive Data on Osteoporosis

    Radius closed at $49.80 on October 13, 2015. During this period, it fell ~34%. Radius is trading below the 20-day, 50-day, and 100-day moving averages.

    By Peter Neil
  • uploads///Graph Part  Dec
    Company & Industry Overviews

    Chimerix Falls 80% following Phase 3 Trial of Brincidofovir

    Chimerix closed at $6.62, and its market-cap fell from $1.6 billion to $305 million on December 28, 2015.

    By Peter Neil
  • uploads///BioMarin Timeline
    Company & Industry Overviews

    Overview of BioMarin: History and Product Portfolio

    Here we present an overview of BioMarin. It’s based in California and was founded in 1997. It focuses on therapies for life-threatening rare genetic diseases.

    By Jillian Dabney
  • uploads///adaadfaedafa
    Company & Industry Overviews

    Xenoport Surges on Takeover Bid and Outperforms the Market

    On May 23, the Dow Jones Industrial Average remained unchanged while the SPDR S&P 500 ETF (SPY) went down by 0.1%. The SPDR S&P 500 ETF rose by 0.75 YTD.

    By Peter Neil
  • uploads///human skeleton _
    Earnings Report

    How Exelixis Is Positioned ahead of Its Q2 2018 Earnings Release

    Exelixis (EXEL) is scheduled to report its second-quarter earnings results on August 1.

    By Daniel Collins
  • uploads///Spectrum
    Company & Industry Overviews

    A Look at Spectrum’s Financial Position in September

    In the second quarter, Spectrum Pharmaceuticals (SPPI) generated net revenues of $24.2 million compared to $34.3 million in Q2 2017.

    By Daniel Collins
  • uploads///Part  Graph
    Company & Industry Overviews

    IBB’s Top Performers: PETX Gains on Its First FDA Approval

    IBB’s top performers for March 21, 2016, were Cara Therapeutics (CARA), OvaScience (OVAS), Sarepta Therapeutics (SRPT), and Aratana Therapeutics (PETX).

    By Peter Neil
  • uploads///sarepta
    Healthcare

    Why Is Sarepta Therapeutics Tanking Today?

    Yesterday, Sarepta Therapeutics received a response from the FDA that raised concerns about its golodirsen new drug application.

    By Margaret Patrick
  • uploads///AdobeStock_
    Earnings Report

    Amarin’s Q2 Earnings and Robust 2019 Outlook

    Amarin Corporation (AMRN) reported its Q2 2019 earnings yesterday. Here’s how the stock, investors, and peer pharma stocks reacted.

    By Sushree Mohanty
  • uploads///Graph
    Company & Industry Overviews

    Analysts Are Optimistic about Sarepta Therapeutics in March

    Wall Street analysts expect a potential upside of 77.04% for Sarepta Therapeutics (SRPT) based on the company’s closing price on March 27.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Sarepta or Amarin: Who’s Expected to Post Faster Revenue Growth?

    Wall Street analysts have projected Sarepta Therapeutics’ revenues to be $395.55 million, $611.37 million, and $1101.00 million, for fiscal 2019, fiscal 2020, and fiscal 2021, respectively.

    By Margaret Patrick
  • uploads///SRPT EPS
    Company & Industry Overviews

    A Look at Sarepta Therapeutics’ Recent Developments

    In the first nine months of 2018, Sarepta Therapeutics’ (SRPT) net income and EPS amounted to -$221.0 million and -$3.38, respectively, compared to -$26.7 million and -$0.47 in the same period the prior year.

    By Daniel Collins
  • uploads///SRPT
    Company & Industry Overviews

    How Is Sarepta Therapeutics Positioned in January?

    In the first nine months of 2018, Sarepta Therapeutics’ net revenues grew ~123% YoY to reach $216.6 million from $97.3 million.

    By Daniel Collins
  • uploads///virus _
    Company & Industry Overviews

    Sarepta Therapeutics Stock Rose 96% in 2018

    On January 4, Sarepta Therapeutics (SRPT) stock closed at $115.43, which represents ~8.21% growth from its prior close.

    By Daniel Collins
  • uploads///SRPT
    Company & Industry Overviews

    Understanding Sarepta Therapeutics’ Operational Performance

    Sarepta Therapeutics’ (SRPT) R&D (research and development) expenses rose YoY (year-over-year) to $86.58 million.

    By Kenneth Smith
  • uploads///BLUE
    Company & Industry Overviews

    Do Analysts See Any Upside for bluebird bio Stock?

    In this year’s third quarter, bluebird bio (BLUE) generated net interest income of $4.59 million.

    By Kenneth Smith
  • uploads///BLUE
    Company & Industry Overviews

    Understanding bluebird bio’s Operational Performance

    In 2018 and 2019, bluebird bio (BLUE) is expected to generate revenues of $43.62 million and $67.0 million, respectively.

    By Kenneth Smith
  • uploads///dna _
    Company & Industry Overviews

    Taking Stock of bluebird bio’s Performance

    In the third quarter, bluebird bio’s total revenue rose YoY (year-over-year) to $11.53 million from $7.71 million.

    By Kenneth Smith
  • uploads///SAGE
    Company & Industry Overviews

    Sage Therapeutics’ Operational Performance

    In fiscal 2018 and fiscal 2019, Sage Therapeutics (SAGE) is expected to generate revenues of $79.41 million and $36.63 million, respectively.

    By Kenneth Smith
  • uploads///nerve cell _
    Company & Industry Overviews

    Sage Therapeutics: Analyzing New Product Candidates

    The Zulresso injection is Sage Therapeutics’ lead product candidate. The company has filed a new drug application.

    By Kenneth Smith
  • uploads///Biomarin
    Company & Industry Overviews

    How BioMarin Pharmaceutical’s Financials Look in November

    BioMarin Pharmaceutical’s (BMRN) net revenues over the first nine months of this year amounted to $1.1 billion compared to $955.3 million in the same period the prior year.

    By Daniel Collins
  • uploads///SRPT
    Company & Industry Overviews

    Analyzing Sarepta’s Product Pipeline

    Sarepta is expected to incur R&D expenses of $277.8 million in fiscal 2018, compared with $166.71 million in fiscal 2017.

    By Kenneth Smith
  • uploads///dna _
    Company & Industry Overviews

    An Investor’s Overview of Sarepta Therapeutics

    Sarepta Therapeutics’ revenues are forecast to be $302.13 million in 2018 and $430.37 million in 2019, up from $154.58 million in 2017.

    By Kenneth Smith
  • uploads///portola products
    Company & Industry Overviews

    Recent Developments for Portola Pharmaceuticals

    In September 2018, the US FDA granted Portola Pharmaceuticals’ cerdulatinib, an investigational Syk/JAK inhibitor, an orphan drug designation for peripheral T-cell lymphoma (or PTCL) therapy.

    By Daniel Collins
  • uploads///pill _
    Company & Industry Overviews

    Look at Acadia Pharmaceuticals Stock: It Rose 7.9% on Tuesday

    On Tuesday, September 25, Acadia Pharmaceuticals (ACAD) stock closed at $21.41. That’s 7.86% higher than its prior day’s close of $19.85.

    By Daniel Collins
  • uploads///headache _
    Company & Industry Overviews

    Analyzing PTC Therapeutics’ Performance in September

    On September 13, PTC Therapeutics’ stock price closed at $47.33, which is ~0.66% growth from the close of $47.02 the previous day.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Sarepta Therapeutics Has Returned 169.97% Year-to-Date

    Sarepta Therapeutics (SRPT) has returned 169.97% YTD. In the second quarter, its EPS was -$0.43, surpassing the consensus estimate by $0.46.

    By Margaret Patrick
  • uploads///dna _
    Company & Industry Overviews

    Audentes Therapeutics’ Promising Product Pipeline

    In this series, we’ll take a look at six stocks with a focus on gene therapy that have promising products in their pipelines.

    By Kenneth Smith
  • uploads///Sarepta ana reco
    Company & Industry Overviews

    What Sarepta Therapeutics’ Valuation Trend Indicates

    Sarepta Therapeutics (SRPT) incurred a net loss of $109.27 million in the second quarter compared to a net loss of $63.05 million in Q2 2017.

    By Kenneth Smith
  • uploads///Sarepta revenues
    Company & Industry Overviews

    Exondys 51 Growth Bodes Well for Sarepta’s Top Line

    For fiscal 2018 and fiscal 2019, Sarepta is expected to generate revenues of $302.25 million and $428.48 million, respectively.

    By Kenneth Smith
  • uploads///laboratory _
    Company & Industry Overviews

    A Look at Incyte’s Valuation on August 22

    On August 22, Incyte was trading at a forward price-to-earnings multiple of 38.1x compared to the industry average of ~13.9x.

    By Mike Benson
  • uploads///microscope _
    Earnings Report

    Sarepta Therapeutics’ Q2 2018 Earnings and Revenue Growth

    Sarepta Therapeutics (SRPT) released its Q2 2018 earnings on August 8, surpassing analysts’ estimates for EPS and revenues.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    What Analysts Recommend for Ionis after Q2 2018

    Wall Street analysts estimate Ionis Pharmaceuticals (IONS) will report year-over-year growth of ~34.8% in revenues to $612.5 million in 2018 as compared to revenues of $507.7 million during 2017.

    By Mike Benson
  • uploads///dna _
    Earnings Report

    How Ionis’s Q2 2018 Earnings Trended

    Ionis reported 5% YoY growth in revenues to $117.7 million during Q2 2018 as compared to $112.3 million during the second quarter of 2017.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Analysts Are Bullish on Sarepta Therapeutics

    Sarepta Therapeutics (SRPT) reported revenues of $64.6 million and a net loss of $0.55 per share in Q1 2018.

    By Mike Benson
  • uploads///dna _
    Earnings Report

    What to Expect from Sarepta’s Second-Quarter Earnings

    Wall Street analysts estimate Sarepta’s revenues will increase by over 100% to $71.6 million in Q2 2018 as compared to revenues of $35.0 million during Q2 2017.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Analysts Have Mixed Opinions about Ionis

    Wall Street analysts estimate that Ionis’s (IONS) Q2 2018 revenues will rise ~30.0% to $135.5 million as compared to $104.2 million in Q2 2017.

    By Mike Benson
  • uploads///baseball __
    Consumer

    NASDAQ All-Stars

    The starting lineup for the Nasdaq All-Stars features names such as MongoDB (NASDAQ: MDB), Etsy Inc. (NASDAQ: ETSY), and Netflix Inc. (NASDAQ: NFLX).

    By JP Gravitt
  • uploads///drugs _
    Company & Industry Overviews

    Why Tonix Pharmaceuticals Stock Soared Today

    Today, Tonix Pharmaceuticals (TNXP) was trading at $4.23, which represents ~7.09% growth from yesterday’s close of $3.95.

    By Daniel Collins
  • uploads///cells __
    Company & Industry Overviews

    What’s behind Gemphire Therapeutics’ Stock Price Rise

    On July 6, Gemphire Therapeutics (GEMP) stock closed at $8.09, ~70% higher than its 52-week low of $4.75 on May 7.

    By Daniel Collins
  • uploads///syringe _
    Company & Industry Overviews

    Analysts Are Mostly Positive on Exelixis in July

    On July 3, Exelixis (EXEL) stock closed at $21.4, a ~15.7% increase from its 52-week low of $18.5 on May 10.

    By Daniel Collins
  • uploads///analysis _
    Company & Industry Overviews

    What Analysts Think of PolarityTE and Its Peers

    In June, PolarityTE stock has been given a “buy” rating by the one analyst covering it. The target price for the stock is $65.

    By Kenneth Smith
  • uploads///microscope _
    Company & Industry Overviews

    Why Summit Therapeutics Stock Crashed Yesterday

    On June 27, Summit Therapeutics announced that its phase two PhaseOut DMD trial failed to meet its primary endpoint.

    By Margaret Patrick
  • uploads///SRPT
    Company & Industry Overviews

    Why Investors Are in a Frenzy over Sarepta Stock in June

    On June 19, Sarepta Therapeutics (SRPT) announced positive preliminary results from its phase one part 2a gene therapy micro dystrophin trial.

    By Kenneth Smith
  • uploads///SRPT
    Company & Industry Overviews

    A Look at Sarepta’s Exondys 51 Commercialization Efforts

    By applying its proprietary platform technologies, Sarepta Therapeutics (SRPT) is able to target a range of diseases and disorders.

    By Kenneth Smith
  • uploads///versartis
    Company & Industry Overviews

    Versartis Stock and Its Consistent Rise in the Week Ended June 8

    Versartis (VSAR) stock rose 48.3% in the week of June 1–8. On June 8, it closed at $2.15.

    By Daniel Collins
  • uploads///pills _
    Company & Industry Overviews

    Analysts’ Ratings for Sarepta Therapeutics and Peers in April

    Of the 19 analysts covering Sarepta Therapeutics in April 2018, six analysts gave the stock a “strong buy” rating.

    By Kenneth Smith
  • uploads///FI
    Company & Industry Overviews

    How BioMarin Pharmaceutical Performed in 4Q17 and 2017

    In 4Q17, BioMarin Pharmaceutical (BMRN) generated revenue of $358.3 million, compared with $300.1 million in 4Q16.

    By Daniel Collins
  • uploads///Spark Therapeutics
    Company & Industry Overviews

    Why Spark Therapeutics Stock Rose in the Week Ended March 29

    On March 29, 2018, Spark Therapeutics was trading at $66.59, which represented a ~62% increase from its 52-week low of $41.06.

    By Daniel Collins
  • uploads///pill _
    Company & Industry Overviews

    Why Did Regeneron Pharmaceuticals’ Stock Price Rise Last Week?

    On March 28, 2018, Regeneron Pharmaceuticals (REGN) was trading at $344.36, a ~9.8% rise from its 52-week low of $313.53.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Sarepta Awaiting Approval for Exondys 51 in Europe

    European market approval On December 20, 2016, Sarepta Therapeutics (SRPT) announced that the MAA (marketing authorization application) for Exondys 51 (eteplirsen) for Duchenne muscular dystrophy (or DMD) patients above four years of age with mutations amenable to exon-51 skipping was accepted by the EC (European Commission). After receiving initial feedback from the EC related to […]

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Confirmatory Studies May Expand Uptake of Exondys 51

    Demand trends Sarepta Therapeutics (SRPT) reported that by the end of 3Q17, all Tier 1 and Tier 2 sites, which will be treating around 75% of DMD (Duchenne muscular dystrophy) patients with mutations amenable to exon-51 skipping, had submitted start forms for Exondys 51 (eteplirsen). The company has also witnessed an increase in start forms submitted […]

    By Margaret Patrick
  • uploads///Part  Graph
    Company & Industry Overviews

    IHI Bucks the Downward Trend for the Week Ending May 6

    For the week ending May 6, the iShares US Medical Devices (IHI) outperformed markets and other biotech ETFs with a return of 0.1%.

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    IBB Returns to Positive: How Did Its Holdings Perform?

    The iShares NASDAQ Biotechnology ETF followed the market trend and gained 1.1% after a five-day losing streak, a positive beginning for the month of May.

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    XBI Had the Best Trading Day Year-to-Date

    The SPDR S&P Biotech ETF (XBI) witnessed the best trading day year-to-date in terms of gains on April 6, 2016.

    By Peter Neil
  • uploads///Graph Geography
    Company & Industry Overviews

    R&D Failure Is the Principal Risk Faced by BioMarin

    The biotechnology industry operates in a dynamic environment embedded with a high-risk business model. The principal risk faced by the industry is R&D failure.

    By Jillian Dabney
  • uploads///Graph pipeline
    Company & Industry Overviews

    BioMarin’s Pipeline for Duchenne Muscular Dystrophy

    There are four drugs in the pipeline targeting Duchenne muscular dystrophy. The company holds Kyndrisa, BMN044, BMN045, and BMN053 for the indication of DMD.

    By Jillian Dabney
  • uploads///Graph Part  Dec
    Company & Industry Overviews

    IBB Small-Caps Reduce Negative Returns in December

    The small-cap stocks of the iShares Nasdaq Biotechnology ETF (IBB) rose 1.4% on December 21, 2015, and reduced the negative returns.

    By Peter Neil
  • uploads///Graph Part  Nov
    Company & Industry Overviews

    IBB Leads Biotech ETFs with Rise of 3.1%

    Markets rose in the week ended November 20, as many believed the FED will hike the interest rate in December. The iShares Nasdaq Biotechnology ETF (IBB) rose 3.1%.

    By Peter Neil
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.